An Open-Label, Phase 1b, Safety/Proof-of-Concept Study to Evaluate the Effects of Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)

Trial Profile

An Open-Label, Phase 1b, Safety/Proof-of-Concept Study to Evaluate the Effects of Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2014

At a glance

  • Drugs Zuretinol acetate (Primary)
  • Indications Retinitis pigmentosa
  • Focus Therapeutic Use
  • Sponsors QLT
  • Most Recent Events

    • 14 Dec 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 03 Mar 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
    • 27 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top